LON:RENX

Renalytix - RENX Share Forecast, Price & News

GBX 87.50

+2.50 (+2.94%)

(As of 03/30/2023 05:06 PM ET)

Add

Compare

Today's Range: 85.50
▼
89.50
50-Day Range: 78
▼
153.85
52-Week Range: 44
▼
349

Volume: 107,331 shs
Average Volume: 72,925 shs
Market Capitalization: £82.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Renalytix (LON:RENX) Stock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Receive RENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

RENX Stock News Headlines

March 30, 2023 | finance.yahoo.com

Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

March 21, 2023 | marketwatch.com

Renalytix Shares Fall on Delay to FDA Marketing Authorization Decision on KidneyIntelX

March 30, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

February 9, 2023 | finance.yahoo.com

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 8, 2023 | finance.yahoo.com

Renalytix announces a c.$20.3 million private placement

January 26, 2023 | marketwatch.com

Renalytix Shares Rise on $10 Mln Grant Award to Advance Chronic Kidney Disease Treatment

January 26, 2023 | finance.yahoo.com

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

January 9, 2023 | finance.yahoo.com

Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems

March 30, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

December 1, 2022 | finance.yahoo.com

Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes

November 30, 2022 | finanznachrichten.de

Renalytix AI, Inc.: Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023

November 30, 2022 | msn.com

What’s going on with the Renalytix share price?

October 31, 2022 | finanznachrichten.de

Renalytix plc: Renalytix Reports Full Year Fiscal 2022 Results

October 24, 2022 | finance.yahoo.com

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31

September 20, 2022 | finance.yahoo.com

Renalytix Announces Change to Board of Directors

August 17, 2022 | uk.finance.yahoo.com

Renalytix Plc (RENX.L)

August 8, 2022 | finance.yahoo.com

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians

June 30, 2022 | fool.co.uk

Here’s why the Renalytix share price is tanking

June 30, 2022 | finance.yahoo.com

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022

June 16, 2022 | uk.finance.yahoo.com

The Renalytix share price – where next?

June 10, 2022 | finance.yahoo.com

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

June 6, 2022 | finance.yahoo.com

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

April 8, 2022 | finance.yahoo.com

Renalytix plc successful completion of $30.0 million financing package

March 31, 2022 | ca.finance.yahoo.com

Renalytix announces a $30.0 million financing package

March 10, 2022 | proactiveinvestors.com

Fragrant Prosperity slumps as reverse takeover falls through

February 24, 2022 | finance.yahoo.com

KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care

February 22, 2022 | lse.co.uk

Renalytix Plc Share Chat

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:RENX
CUSIP: N/A
CIK: N/A
Web: www.renalytixai.com
Phone: 44 20 3139 2910
Fax: N/A
Employees: 51
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-47,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -119.58%
Return on Assets: -62.70%

Debt

Debt-to-Equity Ratio: 59.10
Current Ratio: 2.58
Quick Ratio: 2.42

Sales & Book Value

Annual Sales: £3.46 million
Price / Sales: 24.26
Cash Flow: GBX 48.77 per share
Price / Cash Flow: 1.84
Book Value: GBX 25 per share
Price / Book: 3.58

Miscellaneous

Outstanding Shares: 93,780,000
Free Float: N/A
Market Cap: £83.93 million
Optionable: Not Optionable
Beta: 2.02

Key Executives

Mr. James R. McCullough M.B.A. (Age 55)
CEO & Exec. Director
Comp: $648k

Mr. Fergus Fleming (Age 56)
CTO & Exec. Director
Comp: $449k

Mr. Thomas H. McLain CPA (Age 64)
M.B.A, Pres

Mr. Oliver James Sterling III
Chief Financial Officer

Ms. Andria Parks-Herrera
VP of Marketing

Ms. Jean M. Casner (Age 64)
Sr. VP & Chief HR Officer

Mr. Baljit Singh
Head of Clinical Operations

Dr. Michael J. Donovan M.D. (Age 69)
Ph.D., Chief Medical Officer

Mr. Salim Hamir F.C.A.
Company Sec.

Key Competitors

View All Competitors

RENX Stock - Frequently Asked Questions

How have RENX shares performed in 2023?: Renalytix's stock was trading at GBX 72.50 at the beginning of the year. Since then, RENX stock has increased by 23.4% and is now trading at GBX 89.50.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Renalytix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include United Microelectronics (UMC), Teva Pharmaceutical Industries (TEVA), SSP Group (SSPG), Sarepta Therapeutics (SRPT), Redrow (RDW), QUALCOMM (QCOM), Lloyds Banking Group (LLOY), Entain PLC (GVC.L) (GVC), Gamma Communications (GAMA) and eHealth (EHTH).
What is Renalytix's stock symbol?: Renalytix trades on the London Stock Exchange (LON) under the ticker symbol "RENX."

How do I buy shares of Renalytix?: Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Renalytix's stock price today?: One share of RENX stock can currently be purchased for approximately GBX 89.50.
How much money does Renalytix make?: Renalytix (LON:RENX) has a market capitalization of £83.93 million and generates £3.46 million in revenue each year. The company earns £-47,120,000.00 in net income (profit) each year or GBX (0.55) on an earnings per share basis.
How can I contact Renalytix?: The official website for the company is www.renalytixai.com. The company can be reached via phone at 44 20 3139 2910.

This page (LON:RENX) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial